glucosaminylmuramyl-2-alanine-d-isoglutamine profile

ID Source	ID
PubMed CID	118984439
MeSH ID	M0175090

Synonym
d-alpha-glutamine, n2-(n-(n-acetyl-o-(2-amino-2-deoxy-beta-d-glucopyranosyl)muramoyl)-l-alanyl)-
glucosaminyl-mdp
glucosaminylmuramyl dipeptide
glucosaminyl-muramyl-dipeptide
gmpd
glucosaminylmuramyl-2-alanine-d-isoglutamine
97590-38-0
unii-755sxx41rz
d-glutamine, n-(n-acetyl-4-o-(2-amino-2-deoxy-beta-d-glucopyranosyl)-beta-muramoyl)-l-alanyl-
glucosaminylmuramyl dipeptide [who-dd]
d-glutamine, n-(n-acetyl-4-o-(2-amino-2-deoxy-.beta.-d-glucopyranosyl)-.beta.-muramoyl)-l-alanyl-
d-.alpha.-glutamine, n2-(n-(n-acetyl-o-(2-amino-2-deoxy-.beta.-d-glucopyranosyl)muramoyl)-l-alanyl)-
755SXX41RZ ,
188123-33-3
(2r)-2-[[(2s)-2-[[(2r)-2-[(2r,3r,4r,5s,6r)-3-acetamido-5-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxypropanoyl]amino]propanoyl]amino]-5-amino-5-oxopentanoic acid
Q27266349

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	1 (2.63)	18.7374
1990's	18 (47.37)	18.2507
2000's	9 (23.68)	29.6817
2010's	10 (26.32)	24.3611
2020's	0 (0.00)	2.80

Publication Type	This drug (%)	All Drugs (%)
Trials	3 (6.12%)	5.53%
Reviews	3 (6.12%)	6.00%
Case Studies	1 (2.04%)	4.05%
Observational	0 (0.00%)	0.25%
Other	42 (85.71%)	84.16%

Substance	Studies	Classes	Roles	First Year	Last Year	Average Age	Relationship Strength	Trials	1990's	2000's	2010's
indomethacin	1	aromatic ether; indole-3-acetic acids; monochlorobenzenes; N-acylindole	analgesic; drug metabolite; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; environmental contaminant; gout suppressant; non-steroidal anti-inflammatory drug; xenobiotic metabolite; xenobiotic	1991	1991	33.0	low	0	1	0	0
omeprazole	1	aromatic ether; benzimidazoles; pyridines; sulfoxide		2012	2012	12.0	low	1	0	0	1
acetylglucosamine	1	N-acetyl-D-glucosamine	epitope	2005	2005	19.0	low	0	0	1	0
amoxicillin	1	penicillin allergen; penicillin	antibacterial drug	2012	2012	12.0	low	1	0	0	1
clarithromycin	1	macrolide antibiotic	antibacterial drug; environmental contaminant; protein synthesis inhibitor; xenobiotic	2012	2012	12.0	low	1	0	0	1
glycidyl nitrate	3			1991	2006	23.3	high	0	1	2	0
dactinomycin	1	actinomycin	mutagen	2006	2006	18.0	low	0	0	1	0
ovalbumin	1			1995	1995	29.0	low	0	1	0	0
lipid a	1	dodecanoate ester; lipid A; tetradecanoate ester	Escherichia coli metabolite	1992	1992	32.0	low	0	1	0	0
tuftsin	1	peptide		1995	1995	29.0	low	0	1	0	0

Condition	Studies	First Year	Last Year	Average Age	Relationship Strength	Trials	1990's	2000's	2010's
Ache	1	1998	1998	26.0	low	0	1	0	0
Acute Disease	1	2009	2009	15.0	low	0	0	1	0
Aging	1	1994	1994	30.0	low	0	1	0	0
Animal Mammary Carcinoma	1	1998	1998	26.0	low	1	1	0	0
Ankylosing Spondylarthritis	1	2011	2011	13.0	low	0	0	0	1
B. burgdorferi Infection	1	2017	2017	7.0	low	0	0	0	1
B16 Melanoma	1	2010	2010	14.0	low	0	0	1	0
Benign Neoplasms	3	1997	2006	23.7	low	1	2	1	0
Breast Cancer	1	1998	1998	26.0	low	1	1	0	0
Breast Neoplasms	1	1998	1998	26.0	low	1	1	0	0
Cancer of Lung	2	1990	1998	30.0	low	1	2	0	0
Carcinoma	1	1990	1990	34.0	low	0	1	0	0
Carcinoma, Anaplastic	1	1990	1990	34.0	low	0	1	0	0
Carcinoma, Ehrlich Tumor	1	2010	2010	14.0	low	0	0	1	0
Chronic Disease	2	1997	1998	26.5	low	1	2	0	0
Chronic Illness	2	1997	1998	26.5	low	1	2	0	0
Curling Ulcer	1	2012	2012	12.0	low	1	0	0	1
Delayed Hypersensitivity	2	1991	1995	31.0	low	0	2	0	0
Disease Models, Animal	1	2010	2010	14.0	low	0	0	1	0
Diseases of Immune System	2	1997	2019	16.0	low	0	1	0	1
Duodenal Ulcer	1	2012	2012	12.0	low	1	0	0	1
Emesis	1	1998	1998	26.0	low	0	1	0	0
Endometrioma	1	2013	2013	11.0	low	0	0	0	1
Endometriosis	1	2013	2013	11.0	low	0	0	0	1
Endotoxin Shock	2	1991	2001	28.0	low	0	1	1	0
Experimental Radiation Injuries	1	2015	2015	9.0	low	0	0	0	1
Fibrosarcoma	1	1992	1992	32.0	low	0	1	0	0
Helicobacter Infections	1	2012	2012	12.0	low	1	0	0	1
Herpes Simplex	1	2005	2005	19.0	low	0	0	1	0
Herpes Simplex Virus Infection	1	2005	2005	19.0	low	0	0	1	0
Immune System Diseases	2	1997	2019	16.0	low	0	1	0	1
Infection	1	1997	1997	27.0	low	0	1	0	0
Infections	1	1997	1997	27.0	low	0	1	0	0
Infections, Helicobacter	1	2012	2012	12.0	low	1	0	0	1
Infections, Respiratory	1	2019	2019	5.0	low	0	0	0	1
Itching	1	1998	1998	26.0	low	0	1	0	0
Lung Neoplasms	2	1990	1998	30.0	low	1	2	0	0
Lyme Disease	1	2017	2017	7.0	low	0	0	0	1
Metastase	1	1990	1990	34.0	low	0	1	0	0
Neoplasm Metastasis	1	1990	1990	34.0	low	0	1	0	0
Neoplasms	3	1997	2006	23.7	low	1	2	1	0
Neutropenia	1	1999	1999	25.0	low	0	1	0	0
Osteomyelitis	1	2009	2009	15.0	low	0	0	1	0
Pain	1	1998	1998	26.0	low	0	1	0	0
Palmoplantaris Pustulosis	2	1998	1998	26.0	low	1	2	0	0
Pruritus	1	1998	1998	26.0	low	0	1	0	0
Psoriasis	2	1998	1998	26.0	low	1	2	0	0
Pulmonary Consumption	1	1997	1997	27.0	low	0	1	0	0
Recrudescence	1	1997	1997	27.0	low	0	1	0	0
Respiratory Tract Infections	1	2019	2019	5.0	low	0	0	0	1
Shock, Septic	2	1991	2001	28.0	low	0	1	1	0
Spondylitis, Ankylosing	1	2011	2011	13.0	low	0	0	0	1
Tuberculosis, Pulmonary	1	1997	1997	27.0	low	0	1	0	0
Vomiting	1	1998	1998	26.0	low	0	1	0	0

[Complex treatment of acute hematogenous osteomyelitis in children].
Khirurgiia, , Issue:8, 2009

Comparative study of immunomodulatory properties of muramyl peptides on immune system cells of young and old mice.
Immunopharmacology and immunotoxicology, , Volume: 16, Issue:2, 1994

Inhibition of systemic TNF-alpha cytotoxicity in cancer patients by D-peptidoglycan.
Medical oncology (Northwood, London, England), , Volume: 15, Issue:1, 1998

[The enhancement under the action of a limited diet of the antimetastatic effect due to macrophage activation in mice with Lewis carcinoma].
Eksperimental'naia onkologiia, , Volume: 12, Issue:5, 1990

GMDP and psoriasis.
Lancet (London, England), , Dec-05, Volume: 352, Issue:9143, 1998

The effect of glucosaminylmuramyl dipeptide injection to mice on the course of tuberculous infection and in vitro superoxide anion production.
International archives of allergy and immunology, , Volume: 114, Issue:1, 1997

[Use of the immunopotentiator N-acetyl-glucosamine-N-acetylmuramyl dipeptide during triple anti-Helicobacter pylori therapy].
Terapevticheskii arkhiv, , Volume: 84, Issue:12, 2012

Different effects of the immunomodulatory drug GMDP immobilized onto aminopropyl modified and unmodified mesoporous silica nanoparticles upon peritoneal macrophages of women with endometriosis.
BioMed research international, , Volume: 2013, 2013

Combined effects of synthetic lipid A analogs or bacterial lipopolysaccharide with glucosaminylmuramyl dipeptide on antitumor activity against Meth A fibrosarcoma in mice.
International journal of immunopharmacology, , Volume: 14, Issue:8, 1992

Comparative study of macrophage response in mice after DNA immunization and infection with herpes simplex virus type 1.
Bulletin of experimental biology and medicine, , Volume: 140, Issue:6, 2005

[The principles in correcting secondary immunodeficiencies by using 2 immunomodulators of differing character--purified staphylococcal anatoxin and likopid].
Zhurnal mikrobiologii, epidemiologii i immunobiologii, , Issue:1

[Muramyldipeptide - based compounds in current medicine: focus on glucosaminylmuramyl dipeptide].
Terapevticheskii arkhiv, , Dec-15, Volume: 91, Issue:12, 2019

[Mechanism of action and clinical effectiveness of immunomodulator glucosaminylmuramyl dipeptide (licopide)].
Klinicheskaia meditsina, , Volume: 75, Issue:3, 1997

[Mechanism of action and clinical effectiveness of immunomodulator glucosaminylmuramyl dipeptide (licopide)].
Klinicheskaia meditsina, , Volume: 75, Issue:3, 1997

Inhibition of systemic TNF-alpha cytotoxicity in cancer patients by D-peptidoglycan.
Medical oncology (Northwood, London, England), , Volume: 15, Issue:1, 1998

[The enhancement under the action of a limited diet of the antimetastatic effect due to macrophage activation in mice with Lewis carcinoma].
Eksperimental'naia onkologiia, , Volume: 12, Issue:5, 1990

[Immunomodulators of microbial origin enhance cytotoxicity of human mononuclear leukocytes and reduce metastatic progression of Lewis lung carcinoma in mice].
Zhurnal mikrobiologii, epidemiologii i immunobiologii, , Issue:6

Nonpyrogenic Molecular Adjuvants Based on norAbu-Muramyldipeptide and norAbu-Glucosaminyl Muramyldipeptide: Synthesis, Molecular Mechanisms of Action, and Biological Activities in Vitro and in Vivo.
Journal of medicinal chemistry, , 09-28, Volume: 60, Issue:18, 2017

[Endogenous Tumor necrosis factor alpha unmasks the binding sites for N-acetylglucosaminyl-(beta1-4)-N-acetylmuramyl-alanyl-D-isoglutamine on the surface of melanoma cells].
Bioorganicheskaia khimiia, , Volume: 27, Issue:4

[The enhancement under the action of a limited diet of the antimetastatic effect due to macrophage activation in mice with Lewis carcinoma].
Eksperimental'naia onkologiia, , Volume: 12, Issue:5, 1990

[Immunomodulators of microbial origin enhance cytotoxicity of human mononuclear leukocytes and reduce metastatic progression of Lewis lung carcinoma in mice].
Zhurnal mikrobiologii, epidemiologii i immunobiologii, , Issue:6

Muramyl peptides augment cytotoxic effect of tumor necrosis factor-alpha in combination with cytotoxic drugs on tumor cells.
International immunopharmacology, , Volume: 6, Issue:9, 2006

Inhibition of systemic TNF-alpha cytotoxicity in cancer patients by D-peptidoglycan.
Medical oncology (Northwood, London, England), , Volume: 15, Issue:1, 1998

[Mechanism of action and clinical effectiveness of immunomodulator glucosaminylmuramyl dipeptide (licopide)].
Klinicheskaia meditsina, , Volume: 75, Issue:3, 1997

Study on the reduction of chemotherapy induced neutropenia in mice using glucosaminylmuramyl dipeptide.
Arzneimittel-Forschung, , Volume: 49, Issue:8, 1999

[Complex treatment of acute hematogenous osteomyelitis in children].
Khirurgiia, , Issue:8, 2009

GMDP for psoriasis.
Lancet (London, England), , Aug-15, Volume: 352, Issue:9127, 1998

GMDP for psoriasis.
Lancet (London, England), , Aug-15, Volume: 352, Issue:9127, 1998

GMDP and psoriasis.
Lancet (London, England), , Dec-05, Volume: 352, Issue:9143, 1998

[Glucosaminylmuramyl dipeptide in treatment of respiratory tract diseases].
Vestnik otorinolaringologii, , Volume: 84, Issue:6, 2019

[The clinical economic analysis of application of immune correcting preparations to prevent respiratory infections and their complications in frequently ill children of early school age].
Problemy sotsial'noi gigieny, zdravookhraneniia i istorii meditsiny, , Issue:6

Prevention of experimental septic shock by pretreatment of mice with muramyl peptides.
International immunopharmacology, , Volume: 1, Issue:9-10, 2001

[Increase of the production of tumor necrosis factor in endotoxin shock in mice presensitized with sera of tumor-bearing mice or tumor cell factor].
Biulleten' eksperimental'noi biologii i meditsiny, , Volume: 112, Issue:7, 1991

Single high-dose treatment with glucosaminyl-muramyl dipeptide is ineffective in treating ankylosing spondylitis.
Rheumatology international, , Volume: 31, Issue:8, 2011

The effect of glucosaminylmuramyl dipeptide injection to mice on the course of tuberculous infection and in vitro superoxide anion production.
International archives of allergy and immunology, , Volume: 114, Issue:1, 1997

GMDP for psoriasis.
Lancet (London, England), , Aug-15, Volume: 352, Issue:9127, 1998

[Use of the immunopotentiator N-acetyl-glucosamine-N-acetylmuramyl dipeptide during triple anti-Helicobacter pylori therapy].
Terapevticheskii arkhiv, , Volume: 84, Issue:12, 2012

[Immunomodulators of microbial origin enhance cytotoxicity of human mononuclear leukocytes and reduce metastatic progression of Lewis lung carcinoma in mice].
Zhurnal mikrobiologii, epidemiologii i immunobiologii, , Issue:6

Inhibition of systemic TNF-alpha cytotoxicity in cancer patients by D-peptidoglycan.
Medical oncology (Northwood, London, England), , Volume: 15, Issue:1, 1998

[The enhancement under the action of a limited diet of the antimetastatic effect due to macrophage activation in mice with Lewis carcinoma].
Eksperimental'naia onkologiia, , Volume: 12, Issue:5, 1990

GMDP augments antitumor action of the CP/TNFalpha combination in vivo.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, , Volume: 64, Issue:4, 2010

GMDP and psoriasis.
Lancet (London, England), , Dec-05, Volume: 352, Issue:9143, 1998

The effect of glucosaminylmuramyl dipeptide injection to mice on the course of tuberculous infection and in vitro superoxide anion production.
International archives of allergy and immunology, , Volume: 114, Issue:1, 1997

GMDP augments antitumor action of the CP/TNFalpha combination in vivo.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, , Volume: 64, Issue:4, 2010

[Use of the immunopotentiator N-acetyl-glucosamine-N-acetylmuramyl dipeptide during triple anti-Helicobacter pylori therapy].
Terapevticheskii arkhiv, , Volume: 84, Issue:12, 2012

Different effects of the immunomodulatory drug GMDP immobilized onto aminopropyl modified and unmodified mesoporous silica nanoparticles upon peritoneal macrophages of women with endometriosis.
BioMed research international, , Volume: 2013, 2013

Comparative study of macrophage response in mice after DNA immunization and infection with herpes simplex virus type 1.
Bulletin of experimental biology and medicine, , Volume: 140, Issue:6, 2005

[Comparison of adjuvant activities of glucosaminyl-muramyl dipeptide and of the gene coding for granulocyte-macrophage colony-stimulating factor in DNA immunization against herpes simplex virus].
Molekuliarnaia biologiia, , Volume: 39, Issue:3

Synthesis and immunological evaluation of the conjugates composed from a muramyl peptide GMDP and tuftsin.
International journal of peptide and protein research, , Volume: 45, Issue:4, 1995

[A comparative study of the immunological properties of peptidoglycans of different origins].
Zhurnal mikrobiologii, epidemiologii i immunobiologii, , Issue:1, 1991

[The principles in correcting secondary immunodeficiencies by using 2 immunomodulators of differing character--purified staphylococcal anatoxin and likopid].
Zhurnal mikrobiologii, epidemiologii i immunobiologii, , Issue:1

[Muramyldipeptide - based compounds in current medicine: focus on glucosaminylmuramyl dipeptide].
Terapevticheskii arkhiv, , Dec-15, Volume: 91, Issue:12, 2019

[Mechanism of action and clinical effectiveness of immunomodulator glucosaminylmuramyl dipeptide (licopide)].
Klinicheskaia meditsina, , Volume: 75, Issue:3, 1997

[Mechanism of action and clinical effectiveness of immunomodulator glucosaminylmuramyl dipeptide (licopide)].
Klinicheskaia meditsina, , Volume: 75, Issue:3, 1997

Inhibition of systemic TNF-alpha cytotoxicity in cancer patients by D-peptidoglycan.
Medical oncology (Northwood, London, England), , Volume: 15, Issue:1, 1998

[The enhancement under the action of a limited diet of the antimetastatic effect due to macrophage activation in mice with Lewis carcinoma].
Eksperimental'naia onkologiia, , Volume: 12, Issue:5, 1990

[Immunomodulators of microbial origin enhance cytotoxicity of human mononuclear leukocytes and reduce metastatic progression of Lewis lung carcinoma in mice].
Zhurnal mikrobiologii, epidemiologii i immunobiologii, , Issue:6

Nonpyrogenic Molecular Adjuvants Based on norAbu-Muramyldipeptide and norAbu-Glucosaminyl Muramyldipeptide: Synthesis, Molecular Mechanisms of Action, and Biological Activities in Vitro and in Vivo.
Journal of medicinal chemistry, , 09-28, Volume: 60, Issue:18, 2017

[Endogenous Tumor necrosis factor alpha unmasks the binding sites for N-acetylglucosaminyl-(beta1-4)-N-acetylmuramyl-alanyl-D-isoglutamine on the surface of melanoma cells].
Bioorganicheskaia khimiia, , Volume: 27, Issue:4

GMDP augments antitumor action of the CP/TNFalpha combination in vivo.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, , Volume: 64, Issue:4, 2010

[The enhancement under the action of a limited diet of the antimetastatic effect due to macrophage activation in mice with Lewis carcinoma].
Eksperimental'naia onkologiia, , Volume: 12, Issue:5, 1990

[Immunomodulators of microbial origin enhance cytotoxicity of human mononuclear leukocytes and reduce metastatic progression of Lewis lung carcinoma in mice].
Zhurnal mikrobiologii, epidemiologii i immunobiologii, , Issue:6

Muramyl peptides augment cytotoxic effect of tumor necrosis factor-alpha in combination with cytotoxic drugs on tumor cells.
International immunopharmacology, , Volume: 6, Issue:9, 2006

Inhibition of systemic TNF-alpha cytotoxicity in cancer patients by D-peptidoglycan.
Medical oncology (Northwood, London, England), , Volume: 15, Issue:1, 1998

[Mechanism of action and clinical effectiveness of immunomodulator glucosaminylmuramyl dipeptide (licopide)].
Klinicheskaia meditsina, , Volume: 75, Issue:3, 1997

GMDP for psoriasis.
Lancet (London, England), , Aug-15, Volume: 352, Issue:9127, 1998

[The effect of the immunomodulator glucosaminylmuramyl dipeptide on hematopoiesis in mice with experimental cytopenia].
Radiobiologiia, , Volume: 32, Issue:4

GMDP for psoriasis.
Lancet (London, England), , Aug-15, Volume: 352, Issue:9127, 1998

GMDP and psoriasis.
Lancet (London, England), , Dec-05, Volume: 352, Issue:9143, 1998

GMDP for psoriasis.
Lancet (London, England), , Aug-15, Volume: 352, Issue:9127, 1998

Molecular adjuvants based on nonpyrogenic lipophilic derivatives of norAbuMDP/GMDP formulated in nanoliposomes: stimulation of innate and adaptive immunity.
Pharmaceutical research, , Volume: 32, Issue:4, 2015

The effect of glucosaminylmuramyl dipeptide injection to mice on the course of tuberculous infection and in vitro superoxide anion production.
International archives of allergy and immunology, , Volume: 114, Issue:1, 1997

[Glucosaminylmuramyl dipeptide in treatment of respiratory tract diseases].
Vestnik otorinolaringologii, , Volume: 84, Issue:6, 2019

[The clinical economic analysis of application of immune correcting preparations to prevent respiratory infections and their complications in frequently ill children of early school age].
Problemy sotsial'noi gigieny, zdravookhraneniia i istorii meditsiny, , Issue:6

Prevention of experimental septic shock by pretreatment of mice with muramyl peptides.
International immunopharmacology, , Volume: 1, Issue:9-10, 2001

[Increase of the production of tumor necrosis factor in endotoxin shock in mice presensitized with sera of tumor-bearing mice or tumor cell factor].
Biulleten' eksperimental'noi biologii i meditsiny, , Volume: 112, Issue:7, 1991

Single high-dose treatment with glucosaminyl-muramyl dipeptide is ineffective in treating ankylosing spondylitis.
Rheumatology international, , Volume: 31, Issue:8, 2011

The effect of glucosaminylmuramyl dipeptide injection to mice on the course of tuberculous infection and in vitro superoxide anion production.
International archives of allergy and immunology, , Volume: 114, Issue:1, 1997

GMDP for psoriasis.
Lancet (London, England), , Aug-15, Volume: 352, Issue:9127, 1998

Inhibition of systemic TNF-alpha cytotoxicity in cancer patients by D-peptidoglycan.
Medical oncology (Northwood, London, England), , Volume: 15, Issue:1, 1998

[Use of the immunopotentiator N-acetyl-glucosamine-N-acetylmuramyl dipeptide during triple anti-Helicobacter pylori therapy].
Terapevticheskii arkhiv, , Volume: 84, Issue:12, 2012